Trial Profile
A Randomized, Double Blind, Placebo-controlled, Proof of Concept Study to evaluate Efficacy, Safety and Pharmacokinetics of two Different Doses of SC12267 (20mg, 35 mg) in Patients with Rheumatoid Arthritis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Jun 2011
Price :
$35
*
At a glance
- Drugs Vidofludimus (Primary)
- Indications Rheumatoid arthritis
- Focus Proof of concept; Therapeutic Use
- 11 Jul 2008 Results have been reported at EULAR 2008.
- 29 Nov 2007 Preliminary results reported in a 4SC media release.
- 08 Oct 2007 Status changed from recruiting to in progress.